Abstract

Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.

Drug synergies impact the efficacy of combination therapies but are difficult to identify. Here Narayan et al. describe the drug atlas, a method to predict effective drug combinations from common exclusive drug effects providing a resource for exploring and understanding effective drug combinations.

Details

Title
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Author
Narayan, Ravi S 1 ; Molenaar Piet 2 ; Teng Jian 3 ; Cornelissen, Fleur M, G 4 ; Roelofs, Irene 4 ; Menezes, Renee 5 ; Dik Rogier 6 ; Lagerweij Tonny 7   VIAFID ORCID Logo  ; Broersma Yoran 7 ; Petersen, Naomi 8 ; Marin Soto Jhon Alexander 9 ; Brands Eelke 6 ; van Kuiken Philip 7 ; Lecca, Maria C 10 ; Lenos, Kristiaan J 10 ; In ‘t Veld Sjors G J G 7 ; Wessel, van Wieringen 11 ; Lang, Frederick F 12   VIAFID ORCID Logo  ; Sulman Erik 13   VIAFID ORCID Logo  ; Verhaak Roel 14   VIAFID ORCID Logo  ; Baumert, Brigitta G 15   VIAFID ORCID Logo  ; Stalpers Lucas J A 16   VIAFID ORCID Logo  ; Vermeulen, Louis 17   VIAFID ORCID Logo  ; Watts, Colin 18   VIAFID ORCID Logo  ; Bailey, David 19   VIAFID ORCID Logo  ; Slotman, Ben J 20   VIAFID ORCID Logo  ; Versteeg Rogier 2   VIAFID ORCID Logo  ; Noske, David 21 ; Sminia, Peter 22   VIAFID ORCID Logo  ; Tannous, Bakhos A 3 ; Wurdinger, Tom 4 ; Koster, Jan 2 ; Westerman, Bart A 21   VIAFID ORCID Logo 

 Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands 
 Academic Medical Center, Department of Oncogenomics, Amsterdam, the Netherlands (GRID:grid.5650.6) (ISNI:0000000404654431) 
 Massachusetts General Hospital and Harvard Medical School, Experimental Therapeutics and Molecular Imaging Lab, Neuroscience Center, Neuro-Oncology Unit, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.32224.35) 
 Netherlands Cancer Institute, Department of Psychosocial Research and Epidemiology, Amsterdam, the Netherlands (GRID:grid.430814.a) 
 Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.430814.a) 
 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.430814.a) 
 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.430814.a); Amsterdam UMC, location VUMC, Cancer Center, Department of Medical Oncology, Amsterdam, the Netherlands (GRID:grid.430814.a) 
 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.430814.a); Amsterdam UMC, location VUMC, Cancer Center, Department of Hematology, Amsterdam, the Netherlands (GRID:grid.430814.a) 
10  Amsterdam UMC, location AMC, Cancer Center, Center for Experimental Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR), Amsterdam, the Netherlands (GRID:grid.430814.a) 
11  Amsterdam UMC, location VUMC, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands (GRID:grid.430814.a) 
12  The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Division of Surgery, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
13  NYU Langone Health, Department of Radiation Oncology, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
14  The Jackson Laboratory for Genomic Medicine, Department of Computational Biology, Farmington, USA (GRID:grid.249880.f) (ISNI:0000 0004 0374 0039) 
15  Kantonsspital Graubünden, Loëstrasse 170, Department of Radio-Oncology, Chur, Switzerland (GRID:grid.452286.f) (ISNI:0000 0004 0511 3514) 
16  Academic Medical Center, Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.5650.6) (ISNI:0000000404654431) 
17  Amsterdam UMC, location AMC, Cancer Center, Center for Experimental Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR), Amsterdam, the Netherlands (GRID:grid.5650.6) 
18  University of Birmingham, Edgbaston, Neurosurgery, Institute of Cancer and Genomic Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486) 
19  IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cowley Road, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
20  Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.5335.0) 
21  Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.5650.6) 
22  Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.5650.6) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2412148526
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.